1-4 of 4
Oliver Manzke
Close
Sort by
Journal Articles

A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Thomas S. Larsen, Oliver Manzke, Daniel Leibovitz, Michael Arbushites
Journal: Blood
Blood (2022) 140 (Supplement 1): 12077–12078.
https://doi.org/10.1182/blood-2022-160319
Published: 2022
Journal Articles

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

Myron S. Czuczman, MD, Andrew Davies, BM PhD, Kim M Linton, MBChB, MRCP, PhD, Nina Wagner-Johnston, Randy D. Gascoyne, MD, David A. Eberhard, MD PhD, Gilles Salles, MDPhD, Thomas E. Witzig, MD, Pier Luigi Zinzani, MD, PhD, George W. Wright, PhD, Louis M. Staudt, MD PhD, Jacqueline Repici, Dale Song, Oliver Manzke, MD, Ian D Lewis, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 628.
https://doi.org/10.1182/blood.V124.21.628.628
Published: 2014
Journal Articles

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

Clinical Trials & Observations
Peter Borchmann, Roland Schnell, Irene Fuss, Oliver Manzke, Thomas Davis, Lionel D. Lewis, Detlev Behnke, Claudia Wickenhauser, Petra Schiller, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2002) 100 (9): 3101–3107.
https://doi.org/10.1182/blood-2001-12-0295
Published: 2002
Journal Articles

Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells

Elisabeth Oelmann, Hermann Herbst, Michael Zühlsdorf, Oliver Albrecht, Annette Nolte, Christiane Schmitmann, Oliver Manzke, Volker Diehl, Harald Stein, Wolfgang E. Berdel
Journal: Blood
Blood (2002) 99 (1): 258–267.
https://doi.org/10.1182/blood.V99.1.258
Published: 2002